



FOR IMMEDIATE RELEASE

Contact: Larry Lapila

September 25, 2008

Breckenridge Pharmaceutical signs Letter of Intent with IDL

Boca Raton, Florida– Breckenridge announced today that it has entered into an agreement with IDL to develop and market an ANDA for a cancer drug with U.S. branded sales of approximately \$600 million. Under the terms of this agreement, IDL will develop and manufacturer the product which will be marketed and distributed by Breckenridge. The 2 companies plan to file an ANDA with the FDA in early 2009.

About Breckenridge:

Breckenridge Pharmaceutical is a privately held pharmaceutical marketing, research and development company founded in 1983 that markets a broad range of ValuBrand™ and Generic prescription products in many therapeutic categories. The Breckenridge label is recognized by Wholesalers, Distributors, Chains, and Managed Care Accounts, as well as Retail Pharmacies nationwide. The company markets over 100 products, including multiple ANDA's, in a variety of dosage forms including: Tablets, Capsules, Soft Gel Capsules, Liquids, Suspensions and Topical preparations. www.bpirx.com

About IDL:

IDL “International Drug Licensing”, located in Paris, France, is a dedicated drug development consulting company founded in 1985, and is now part of DELPHARM Group, one of the leading Contract Manufacturing Organizations in Europe with a plant dedicated for manufacturing oncology and hormonal products.

For Further Information, please contact:

Breckenridge Pharmaceutical

Larry Lapila, Vice President Business
Development

TEL: 860-828-8140 FAX: 860-828-8142

e-Mail: llapila@bpirx.com

IDL “International Drug Licensing”

Pierre Charrier, Marketing and Sales Director

e-Mail : pierre.charrier@delpharm.com